Risk of Hemorrhagic Stroke among Patients Treated with High-Intensity Statins versus Pitavastatin-Ezetimibe: A Population Based Study
Tohoku J Exp Med. 2024 Feb 22. doi: 10.1620/tjem.2024.J019. Online ahead of print.NO ABSTRACTPMID:38382969 | DOI:10.1620/tjem.2024.J019 (Source: The Tohoku Journal of Experimental Medicine)
Source: The Tohoku Journal of Experimental Medicine - February 21, 2024 Category: Research Authors: Po-Sheng Chen Jia-Ling Lin Hui-Wen Lin Sheng-Hsiang Lin Yi-Heng Li Source Type: research
Poor results with “Best Medical Therapy” in patients with asymptomatic carotid stenosis
In a recent paper in this journal, Oliveira et al.1 present the poor results of medical therapy in their patients with asymptomatic carotid stenosis (ACS). Among their most recent 120 patients with ACS, “Blood pressure control, normal weight, statin with/without ezetimibe association, and antiaggregant therapy were only achieved in 33 patients and only 5 had additionally low-density lipoprotein levels (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - February 21, 2024 Category: Surgery Authors: J. David Spence Tags: Correspondence Source Type: research
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis
In conclusion, our study presents ezetimibe as a potential novel therapeutic for idiopathic pulmonary fibrosis.PMID:38359963 | DOI:10.1183/13993003.00580-2023 (Source: Respiratory Care)
Source: Respiratory Care - February 15, 2024 Category: Respiratory Medicine Authors: Chanho Lee Se Hyun Hyun Jisu Han Ju Hye Shin Byunghun Yoo Yu Seol Lee Jeong Su Park Beom Jin Lim Jin Gu Lee Young Sam Kim Song Yee Kim Soo Han Bae Source Type: research
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
CONCLUSION: Addition of ezetimibe to high-intensity statin therapy at the time of ACS event is associated with significantly better cholesterol reduction at day-7,1-month, 3- months and 1-year of follow-up, which translates into a significantly lower recurrent cardiovascular events post an index event of ACS.CONCISE SUMMARY OF FINDINGS: Addition of ezetimibe to high-intensity statin therapy at the time of acute coronary syndrome (ACS) index event is associated with significantly better low density lipoprotein cholesterol and total cholesterol reduction at day-7, 1-month, 3-months and 1-year of follow-up, which translates i...
Source: European Journal of Internal Medicine - February 9, 2024 Category: Internal Medicine Authors: Kunal Mahajan Lakshmi Nagendra Anil Dhall Deep Dutta Source Type: research
Combining Ezetimibe and Rosuvastatin: Impacts on Insulin Sensitivity and Vascular Inflammation in Patients with Type 2 Diabetes Mellitus
Diabetes Metab J. 2024 Jan;48(1):55-58. doi: 10.4093/dmj.2023.0442. Epub 2024 Jan 29.NO ABSTRACTPMID:38317513 | PMC:PMC10850279 | DOI:10.4093/dmj.2023.0442 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - February 6, 2024 Category: Endocrinology Authors: Eun Roh Source Type: research
Dyslipidaemia in elderly and stroke patients
Indian Heart J. 2024 Feb 2:S0019-4832(24)00013-0. doi: 10.1016/j.ihj.2024.01.013. Online ahead of print.ABSTRACTLowering of cholesterol containing atherogenic particles through lipid lowering therapies is of outmost important in both in the elderly age group and younger age group in reducing the cardiovascular risk. This chapter summarizes the current existing knowledge regarding the factors which affects the key decision-making process in patients with older age, and also in special circumstance where the direct evidence of benefit for cholesterol lowering is lacking. Effort has been made to briefly summarize the recommen...
Source: Indian Heart J - February 3, 2024 Category: Cardiology Authors: Dhiman Kahali Source Type: research
Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data
ConclusionsLipid testing and lipid-lowering medications for cardiovascular disease prevention generate substantial real-world costs which can be used to improve cost-effectiveness models of familial hypercholesterolemia screening and care management. (Source: High Blood Pressure and Cardiovascular Prevention)
Source: High Blood Pressure and Cardiovascular Prevention - February 3, 2024 Category: Cardiology Source Type: research
Treatment of dyslipidemia in acute coronary syndrome
Indian Heart J. 2024 Feb 1:S0019-4832(24)00011-7. doi: 10.1016/j.ihj.2024.01.011. Online ahead of print.ABSTRACTDespite numerous improvements in the management of acute coronary syndrome(ACS), it is a major cause of mortality in India. Lipids play a critical role in pathogenesis of ACS and reduction of lipid parameters plays a pivotal role in secondary prevention. High total cholesterol and high low-density lipoprotein(LDL) are the major lipid abnormalities globally as well as in Indians. Among all the lipid parameters, LDL is the primary target of lipid-lowering therapies across the globe. High-dose statins, ezetimibe, pr...
Source: Indian Heart J - February 2, 2024 Category: Cardiology Authors: Satyavir Yadav Jitendra Pal Singh Sawhney Source Type: research
How Will Our Practice Change After the CLEAR Outcomes Trial?
AbstractPurpose of ReviewBempedoic acid is a novel therapeutic agent that is designed to reduce levels of low-density lipoprotein cholesterol (LDL-C). The purpose of this review is to provide the background for development of bempedoic acid, findings from clinical trials and to discuss clinical implications.Recent FindingsBempedoic acid inhibits ATP citrate lyase within the liver and reduces cholesterol synthesis, with the potential to avoid muscle symptoms experienced by patients treated with statins. Early clinical studies demonstrated that administration of bempedoic acid resulted in lowering of LDL-C by 20 –30% as mo...
Source: Current Atherosclerosis Reports - January 31, 2024 Category: Cardiology Source Type: research
Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
AbstractPurpose of ReviewChronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular disease (CVD). This review summarizes known risk factors, pathophysiological mechanisms, and current therapeutic possibilities, focusing on lipid-lowering therapy in CKD.Recent FindingsNovel data on lipid-lowering therapy in CKD mainly stem from clinical trials and clinical studies.SummaryIn addition to traditional CVD risk factors, patients with CKD often present with non-traditional risk factors that include, e.g., anemia, proteinuria, or calcium-phosphate imbalance. Dyslipidemia remains an important ...
Source: Current Atherosclerosis Reports - January 30, 2024 Category: Cardiology Source Type: research
Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study
ConclusionThis real-world study confirms that statin-treated high-risk patients with ASCVD and above-threshold LDL-C levels have substantial incidence of recurrent CV events. These findings reinforce the opportunity for lipid-lowering therapy intensification in high-risk patients to levels below guideline-recommended threshold in order to reduce CV risk. (Source: Cardiology and Therapy)
Source: Cardiology and Therapy - January 29, 2024 Category: Cardiology Source Type: research
Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial
CONCLUSION: Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg). Both medication therapies were safe in patients, and the increased dose of monotherapy showed more side effects than the combination therapy.PMID:38275031 | DOI:10.2174/0118715257274373231211060714 (Source: Cardiovascular and Hematological Agents in Medicinal Chemistry)
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - January 26, 2024 Category: Cardiology Authors: An Viet Tran Bao Lam Thai Tran Nghia Minh Bui Anh Tan To Le Diem Thi Nguyen Son Kim Tran Toan Hoang Ngo Source Type: research
Managing dyslipidaemia in patients with chronic kidney disease
Indian Heart J. 2024 Jan 24:S0019-4832(24)00012-9. doi: 10.1016/j.ihj.2024.01.012. Online ahead of print.ABSTRACTPatients with CKD are at increased risk for cardiovascular events. Clinical studies suggest statins reduce all-cause mortality and cardiovascular events in patients with CKD. Lipid lowering therapy with statin with or without ezetemibe is recommended for most of the patients in patients with eGFR <60 mL/min and also in those who have an increased urinary albumin-to-creatinine ratio (≥3 mg/mmol) for at least 3 months. Evidence suggests that it should not be started for hemodialysis patients without evidence ...
Source: Indian Heart J - January 26, 2024 Category: Cardiology Authors: Ashwani Mehta Source Type: research
Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome
CONCLUSION: Through stepwise intensification of lipid-lowering therapy, 84% of very high-risk post-ACS patients achieved an LDL‑C target of ≤ 1.8 mmol/l with oral medications alone. Addition of PCSK9i further increased this rate to 87% (95% CI: 85-89).PMID:38277062 | DOI:10.1007/s12471-023-01851-7 (Source: Netherlands Heart Journal)
Source: Netherlands Heart Journal - January 26, 2024 Category: Cardiology Authors: Aaram Omar Khader Tinka van Trier Sander van der Brug An-Ho Liem Bjorn E Groenemeijer Astrid Schut Harald T Jorstad Fabrice M A C Martens Marco A M W Alings Source Type: research
Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions
ConclusionsPBPK model-predicted ezetimibe and EZE-glucuronide exposures and UAR suggest that breastfeeding infants would receive non-therapeutic exposures. Future work should involve a ‘mother-infant pair study’ to ascertain breastfed infant plasma ezetimibe and EZE-glucuronide concentrations to confirm the findings of this work. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - January 26, 2024 Category: Drugs & Pharmacology Source Type: research
